We have observed
2 EP applications
Nikolai Graf Keyserlingk
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after October 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
NOVEL RECOMBINANT CLOSTRIDIAL NEUROTOXINS WITH DECREASED DURATION OF EFFECT
NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH ACCELERATED ONSET OF EFFECT